Comparison of carvedilol and metoprolol for preventing contrast-induced nephropathy after coronary angiography

Cardiorenal Medicine, 06/22/2015

Yilmaz M, et al. – The aim of this study was to analyze and compare the effects of carvedilol and metoprolol on the development of contrast–induced nephropathy (CIN) in patients undergoing coronary angiography. When compared to metoprolol, carvedilol might decrease oxidative stress and subsequent development of CIN.

Methods

·         One hundred patients currently taking metoprolol and 100 patients currently taking carvedilol were enrolled into the study.

·         Venous blood samples were obtained before and 48 h after contrast administration.

·         Cystatin C and malondialdehyde values were examined and compared.

CIN was defined as a creatinine increase of at least 25% or 0.5 mg/dl from the baseline value.

Results

·         Seven patients in the carvedilol group (7%) and 22 patients in the metoprolol group (22%) developed CIN (p = 0.003).

·         In the metoprolol group, the median cystatin C concentration increased significantly from 978 to 1,086 ng/ml (p = 0.001) 48 h after radiocontrast administration.

·         In the carvedilol group, the median cystatin C concentration did not change significantly (1,143 vs. 1,068 ng/ml; p = 0.94).

·         In the metoprolol group, the mean malondialdehyde concentration increased significantly from 7.09 ± 1.48 to 8.38 ± 2.6 nmol/l (p < 0.001).

·         In the carvedilol group, the mean serum malondialdehyde concentration did not change significantly (7.44 ± 1.21 vs. 7.56 ± 1.11 nmol/l; p = 0.59).

Source: www.mdlinx.com